Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
8-Chloro-cyclic Adenosine Monophosphate in Treating Patients With Recurrent or Refractory Multiple Myeloma
This study has been completed.
Sponsored by: | National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 8-chloro-cyclic adenosine monophosphate in treating patients who have recurrent or refractory multiple myeloma.
Condition | Treatment or Intervention | Phase |
---|---|---|
stage II multiple myeloma stage III multiple myeloma stage I multiple myeloma refractory plasma cell neoplasm |
Drug: -chloro-cyclic adenosine monophosphate |
Phase II |
MedlinePlus related topics: Immune System and Disorders; Lymphatic Diseases; Multiple Myeloma
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Pilot Study of 8-Chloro-cyclic Adenosine Monophosphate (8-Chloro-cAMP) in Patients With Recurrent or Refractory Multiple Myeloma
Study start: October 1999
OBJECTIVES: I. Determine the safety of 8-chloro-cyclic adenosine monophosphate (8-chloro-cAMP) in patients with recurrent or refractory multiple myeloma.
II. Evaluate the efficacy of this regimen in these patients.
III. Determine the pharmacokinetics of this regimen in these patients.
PROTOCOL OUTLINE: Patients receive 8-chloro-cyclic adenosine monophosphate (8-chloro-cAMP) over 120 hours every 2 weeks for up to 4 courses. Beginning with course 5, patients with stable or responsive disease receive 8-chloro-cAMP over 120 hours every 3 weeks until disease progression.
Patients are followed every 3 months until death.
PROJECTED ACCRUAL: A maximum of 29 patients will be accrued for this study within 12-18 months.
Eligibility
Ages Eligible for Study: 18 Years and above
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |